Compare Ascendis Pharma A/S (ASND) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Northrop Grumman Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Northrop Grumman Corporation trades at $540.5 (market cap $76.65B). The key difference: Northrop Grumman Corporation is far larger — about 4.3× Ascendis Pharma A/S's market cap, and Northrop Grumman Corporation pays a 1.74% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NOC | |
|---|---|---|
Market Cap | $17.74B | $76.65B |
Sector | Health | Industrials |
52-Week High | $277.18 | $768.02 |
52-Week Low | $163.32 | $496.02 |
Enterprise Value | $18.11B | $90.87B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Northrop Grumman (NOC) trades at $539.63, up 1.39% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a $95.61B backlog, 10.8% net margin, and consistent cash flow growth. Analyst consensus remains bullish with a $694.40 price target, though technical indicators show resistance near $542.
NOC presents a compelling value opportunity with reasonable valuation (P/E 16.92) and strong defense sector positioning. Key risks include political budget uncertainty and execution challenges. The upcoming Q2 earnings on July 21, 2026, will be crucial for confirming growth trajectory amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
